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Introduction: Nuclear accumulation of β-catenin is important for cancer development and it is found to overlap
with p68 (DDX5) immunoreactivity in most breast cancers, as indicated by both clinical investigations and studies in
cell lines. In this study, we aim to investigate the regulation of p68 gene expression through β-catenin/transcription
factor 4 (TCF4) signaling in breast cancer.
Methods: Formalin-fixed paraffin-embedded sections derived from normal human breast and breast cancer samples
were used for immunohistochemical analysis. Protein and mRNA expressions were determined by immunoblotting and
quantitative RT-PCR respectively. Promoter activity of p68 was checked using luciferase assay. Occupancy of several
factors on the p68 promoter was evaluated using chromatin immunoprecipitation. Finally, a syngeneic mouse model of
breast cancer was used to assess physiological significance.
Results: We demonstrated that β-catenin can directly induce transcription of p68 promoter or indirectly through
regulation of c-Myc in both human and mouse breast cancer cells. Moreover, by chromatin immunoprecipitation assay,
we have found that both β-catenin and TCF4 occupy the endogenous p68 promoter, which is further enhanced by
Wnt signaling. Furthermore, we have also established a positive feedback regulation for the expression of TCF4 by p68.
To the best of our knowledge, this is the first report on β-catenin/TCF4-mediated p68 gene regulation, which plays an
important role in epithelial to mesenchymal transition, as shown in vitro in breast cancer cell lines and in vivo in an
animal breast tumour model.
Conclusions: Our findings indicate that Wnt/β-catenin signaling plays an important role in breast cancer progression
through p68 upregulation.Introduction
Compelling evidences indicate that the Wnt/β-catenin sig-
naling is implicated in different stages of mammary gland
development and is also important for mammary onco-
genesis when aberrantly activated [1-5]. Genetic mutations
in adenomatous polyposis coli (APC) and catenin (cad-
herin-associated protein) beta 1 (CTNNB1), the com-
ponents of the Wnt/β-catenin signaling pathway, are the* Correspondence: mrinal.res@gmail.com
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unless otherwise stated.major contributors of colorectal cancer although they are
typically not the key factors associated with breast cancer.
It has been demonstrated that only 6% of breast tumours
contain mutations in the APC gene but no mutations were
detected in CTNNB1 [6,7]. However, Wnt proteins (1, 3a,
4, 5a, 7b, 10b and 14) [8-10] and multiple Frizzled receptors
(Fzd4/7) are reported to be overexpressed in human breast
cancer cell lines and primary tumours [11,12]. Recently, it
has been documented that low-density lipoprotein-related
protein (LRP)6 but not LRP5 is frequently upregulated in a
subset of human breast carcinomas and downregulation of
LRP6 is sufficient to inhibit breast cancer tumourigenesis
[13]. Moreover, Dishevelled 1 (DVL1), a central regulator of
Wnt signaling is found to be upregulated in breast cancerThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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antagonists secreted Frizzled-related proteins (sFRPs)
and Wnt inhibitory factor-1 (WIF-1) leads to aberrant
regulation of Wnt/β-catenin signaling in both primary
breast tumours and cell lines [15-17]. Again, approxi-
mately 60% of primary breast tumours show cytoplas-
mic or nuclear accumulation of β-catenin rather than
its membrane localization, and this is correlated with
poor prognosis [18].
p68 was first discovered through its immunological
cross-reactivity with the anti-SV40 large T monoclonal
antibody [19]. Molecular similarity of p68 (an ATP-
dependent RNA helicase) with both the large T antigen
and eIF-4A (an ATP-dependent DNA helicase) implied
that p68 may function as both RNA and DNA helicase
[20]. Moreover, p68 knockout mice are embryonically
lethal (E11.5), indicating its importance in the develop-
ment process [21]. p68 was shown to bind, unwind and
rearrange RNA secondary structures and it is also a cru-
cial factor in the processing, alternate splicing and deg-
radation of mRNA [22-24]. Subsequently, p68 has been
implicated in a wide range of biological processes, and
early studies of this protein indicate its possible involve-
ment in the regulation of proliferation and organ differ-
entiation [22]. Recently, p68 has been demonstrated to
act as a potent transcriptional co-activator of estrogen
receptor [25,26], androgen receptor [27], tumour sup-
pressor p53 [28], MyoD [29] and β-catenin [30]. p68’s
activation as a result of its phosphorylation at Tyr593 by
platelet-derived growth factor (PDGF) was shown to be
associated with cellular transformation and epithelial to
mesenchymal transition (EMT) in colon cancer by pro-
moting nuclear translocation of β-catenin, and upregula-
tion of its target genes like cyclin D1 and c-myc [31,32].
In addition to this, modification of p68 by the small
ubiquitin-like modifier SUMO-2 was found to modulate
its activity as a transcriptional regulator, favouring re-
pression [33]. It has been found that p68 is constitutively
overexpressed in various cancers like colon [34], breast
[35], prostate [27], head and neck as well as cutaneous
squamous cell carcinoma [36]. Serum-induced p68 ex-
pression in Swiss 3 T3 fibroblasts is involved in cellular
proliferation and also connected to organ differentiation
and maturation of the foetus [37].
p68 regulates the expression of several oncogenes
through co-activation of β-catenin-mediated transcription,
and controls tumour growth and metastasis. Although,
there is an expansive evidence of literature deciphering
the central role of p68 with respect to β-catenin in the
architecture of intracellular signaling networks, little is
known about its transcriptional regulation that may con-
tribute to cancer development. Moreover, cellular conse-
quences due to the modulation of its expression are not
yet completely understood. Such knowledge might provideinvaluable insights into the molecular mechanisms with
respect to p68 in the context of oncogenesis.
Methods
Cell culture, transfection and drug treatments
HEK293T (human embryonic kidney); MCF7, MDA-MB
231 (human breast cancer); 4T1 (mouse breast cancer);
H1299 (lung adenocarcinoma) and HCT116 (colon can-
cer) cell lines used in this study were obtained from the
American Type Culture Collection (ATCC). Cell culture
and transfections were performed using standard pro-
cedure as described previously [38]. Small interfering
RNAs (siRNAs) were purchased from Sigma-Aldrich (St
Louis, MO, USA) (β-catenin), Cell Signaling Technology
(Beverly, MA, USA) (p68) and Santa Cruz Biotechnology
(Santa Cruz, CA, USA) (tcf4 and c-myc). G418 (2 mg/
ml)-resistant MCF7 stable cells were selected by homo-
geneous colony formation as described earlier [39].
Wnt3A conditioned medium
Wnt3a-L cells were split at the ratio of 1:10 in 10 ml
medium using standard procedure. Medium was col-
lected from two consecutive batches of cells cultured for
four days. Wnt-3a conditioned medium (Wnt3a-CM)
was either freshly used with serum-free media (1:1) or
stored at 4°C until further use.
Expression plasmids
The human wnt3a gene was cloned in pcDNA4/TO and
further sub-cloned into pcDNA3.1-myc-his. Cloning of
c-myc in pcDNA3.1-myc-his was done previously [40].
pEGFP-c1-β-catenin and pEGFP-c1-p68 were sub-cloned
from pGZdx-β-catenin and pGS5-p68 respectively. Human
and mouse p68 promoters (-1200 to +200 and -1200 to +
175 respectively) were cloned in pGL3-basic plasmid. Point
mutations in these p68 promoters were generated by Site-
Directed Mutagenesis using QuikChange XL kit (Strata-
gene, San Diego, CA, USA). Transcription factor 4 (TCF4)
promoter (-1001 to +303) was cloned into pGL3-basic plas-
mid. All the constructs were verified by restriction diges-
tions and confirmed by sequencing. Sequences of all the
primers used are available in Table S1 in Additional file 1.
Immunocytochemistry (ICC)
For ICC, cells were processed as described earlier [41].
Briefly, after permeabilization, cells were incubated with
primary antibodies (1:200) overnight at 4°C followed by in-
cubation with Alexa Fluor (488 or 594)-tagged secondary
antibodies (1:500) (Molecular Probes, Eugene, OR, USA).
Primary antibodies (β-catenin and TCF4) were purchased
from Cell Signaling Technology. Images were taken with
BX61 upright fluorescence microscope (Olympus, Center
Valley, PA, USA) using Image-Pro Plus software (Media
Cybernetics, Silver Spring, MD, USA).
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Preparation of whole cell lysates (WCL), cytoplasmic and
nuclear extracts and IB were performed as described pre-
viously [41]. Either GAPDH or β-actin was used as a load-
ing control. Primary antibodies were purchased from
Abcam (Cambridge, UK) (p68), Cell Signaling Technology
(β-catenin, Cyclin D1, c-Myc, TCF4, Myc-Tag, E-cadherin,
N-cadherin and Vimentin) and Santa Cruz Biotechnology
(GAPDH, α-Tubulin, LaminB, β-actin and TCF4). Horse-
radish peroxidase (HRP)-tagged anti-rabbit and anti-goat
secondary antibodies used were from Cell Signaling Tech-
nology and Sigma-Aldrich respectively.
Quantitative RT-PCR (qRT-PCR)
Total RNA was extracted and converted to cDNA,
which was subsequently used for qRT-PCR analysis [40]
using Power SYBR Green Master Mix on a 7500 Fast
Real-Time PCR system (Applied Biosystems, Carlsbad,
CA, USA). 18S rRNA served as the internal control.
Sequences of all the primers used in qRT-PCR are given
in Table S1 in Additional file 1. Standard deviation (SD)
calculations are based on three technical replicates of
two independent biological repeats.
Luciferase assays
Cells were transiently transfected with pGL3-p68 pro-
moter luciferase reporter construct(s) along with Renilla
luciferase plasmid (pRL-TK) and subjected to various
treatments as indicated in the relevant figure(s). Luciferase
activity was determined by luminometry using the GLO-
MAX 20/20 luminometer (Promega, Madison, WI, USA)
by the dual-luciferase assay system (Promega), as specified
by the manufacturer. Quantification was based on three
technical replicates over at least two independent bio-
logical repeats.
Chromatin immunoprecipitation (ChIP)
Sonicated cross-linked chromatin fragments were pre-
pared from cells treated with formaldehyde as described
earlier [41,42]. Briefly, equal amounts of all pre-cleared
chromatin fragments (250 μg) were incubated with
primary antibodies for 12 h at 4°C followed by pull
down with 3% bovine serum albumin (BSA)-blocked
protein G sepharose beads. Primary antibodies against
β-catenin, TCF4, c-Myc and normal rabbit immuno-
globulin G (IgG) were purchased from Cell Signaling
Technology. Purified DNAs from immunoprecipitated
chromatin fragments were used in PCR reactions with a
standard programme using Qiagen’s Top Taq master
mix (Qiagen, Venlo, Netherlands). The PCR products
were analysed in 2% agarose gel. Quantitative RT-PCR
(qRT-PCR) reactions were performed using SYBR Green
master mix. All the primers used are listed in Table S1
in Additional file 1.Soft agar colony formation assay and invasion assay
Colony formation assays in soft agar were performed in
triplicate as described earlier [43]. Images were cap-
tured by Olympus IX81 microscope using Image-Pro
Plus software (Olympus) at 100× optical magnification
and colony-forming efficiency was quantified. Matrigel
invasion assay was performed as described previously
[44]. Images were captured by Olympus IX81 micro-
scope at 40X magnification. Statistical analysis was per-
formed by Student’s t test using GraphPad software
with level of significance P <0.001 (GraphPad Software,
San Diego, CA, USA).
Immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded (FFPE) tissue sec-
tions derived from normal human breast (n = 10) and
breast cancer samples (n = 20) were obtained from
Indian patients after formal approval from ethical com-
mittee of both Council of Scientific and Industrial
Research (CSIR)-Indian Institute of Chemical Biology
(IICB) and Park Clinic (registered under WB Societies
Act. 1961). All patients involved in the study agreed to
participate and publish the research outcome. IHC was
performed and H-scores were calculated as described
previously [45]. Primary antibodies were from Abcam
(p68 and Snail), Cell Signaling Technology (TCF4, E-
cadherin, proliferating cell nuclear antigen (PCNA) and
Vimentin) and Santa Cruz Biotechnology (β-catenin).
Orthotopic syngeneic mouse model of breast cancer
All animal care and experimentation conformed to the
Committee for the Purpose of Control and Supervision of
Experiments on Animals (CPCSEA) (Govt. of India) fol-
lowing internationally recognized guidelines. The animal
ethics approval was granted by ‘IICB-Animal Ethics Com-
mittee (IICB-AEC), CSIR, Govt. of India’. To generate the
tumour model, three- to four-week-old BALB/c mice were
injected once with either EV or p68 knockdown 4T1 stable
cells (1 × 105) in the mammary fat pad region. Growth of
the tumour was observed for a period of 21 days after
which the mice were sacrificed and the tumours were
excised, fixed in 10% buffered formalin and embedded in
paraffin for further IHC analysis.
Statistical analysis and densitometry
All statistical calculations were done using GraphPad
QuickCalcs calculator, [46]. For the analysis of statis-
tical significance of the H scores, U test or Student’s t
test (unpaired) was used. In all the experiments a value
of P <0.05 was considered as statistically significant.
Image quantification and densitometric scanning of im-
munoblots were done using Image J software (Bethesda,
MD, USA).
Guturi et al. Breast Cancer Research  (2014) 16:496 Page 4 of 15Results
Canonical Wnt signaling regulates p68 expression
Canonical Wnt signaling in human colon and breast can-
cer cells plays a key role for the aberrant activation of the
β-catenin/TCF4 in tumour progression. Like β-catenin,
p68 is an important transcriptional regulator, crucial for
early growth and development and is also associated with
cell proliferation [37,47]. Overexpression of p68 is com-
mon in most of the human tumours including breast [30].
Here, we are interested in investigating the possible
connections among these intensively studied oncogenes.
To address this issue, we first examined the expression
of β-catenin, TCF4 and p68 in various established cancer
cell lines and HEK293T cells (Figure 1a). We have also
analysed the expression pattern of these molecules by
IHC analysis in human breast tumour and normal
samples (Figure 1b and Figure S1 in Additional file 2)
and classified based on the E-cadherin expression status
[48-50]. The results indicate that there is a probable cor-
relation for β-catenin and TCF4 with p68 in the cancer
cell lines. Moreover, this positive correlation was also
found in E-cadherin null samples (Figures 1b and c). Our
results also indicate that p68 expression is quite low in
MCF-7 cells as compared to highly metastatic MDA-MB
231 and mouse 4T1 cells with reduced expression or
absence of E-cadherin, which is corroborated with the
previous findings in breast tumours and cell lines [35].
Since Wnt3a is known to stabilize β-catenin and in-
crease its nuclear accumulation, we generated constitu-
tively expressing Wnt3a stable MCF7 (Wnt3a-MCF7)
cells and examined the cytoplasmic/nuclear distribution
of β-catenin in these cells under serum-starved con-
ditions. Here, we visualised the localisation pattern of
β-catenin by both immunofluorescence and IB and ob-
served an increased level of β-catenin in the nucleus of
these cells when compared to the empty vector- contain-
ing control (EV-MCF7) cells (Figure 1d). Wnt3a-MCF7
cells showed a significant increase in p68 level along
with β-catenin and its targets Cyclin D1 and Axin-2
(positive control) compared to EV-MCF7 (Figure 1e). To
strengthen our finding, we have analysed p68 expression
in various breast cancer cell lines under enhanced Wnt
signaling by Wnt3a-CM treatment. We observed that
Wnt3a-CM upregulates p68 expression at both protein
and mRNA level (Figures 1f and g), where Cyclin D1
was kept as a positive control. We have further observed
a similar effect in HEK293T and other cancer cell lines
(Figure S2 in Additional file 3). Further, we observed
that the stabilized β-catenin due to GSK3β inactivation
in lithium chloride (LiCl)-treated serum-starved MCF7
cells, leads to increased expression of p68, where Cyclin
D1 served as positive control (Figure S3 in Additional
file 4). Collectively, all these results clearly indicate that
p68 expression is controlled by Wnt/β-catenin signaling.β-catenin and TCF4 control p68 transcription
It was interesting for us to discern the role of β-catenin in
the regulation of the p68 gene expression. For this, we
transiently overexpressed β-catenin in MCF7 cells and ex-
amined its effect on p68 expression, which increased with
enhanced expression of β-catenin in a dose-dependent
manner (Figure 2a). Again, to understand whether this
regulation is a transcriptional or post-translational event,
we overexpressed β-catenin in the presence of either cy-
cloheximide (CHX, translational inhibitors) or actinomy-
cin D (AD, transcriptional blocker). In the presence of
overexpressed β-catenin, increased expression of p68 was
drastically diminished by transcriptional inhibition rather
than translational inhibition (Figures 2b and c).
To further support these results we have investigated this
β-catenin/TCF4-mediated p68 gene regulation in both
mouse 4T1 and human HEK293T cells. Here, we observed
that overexpression of either β-catenin or TCF4 leads to in-
creased expression of p68 along with Wnt targets c-Myc
and Cyclin D1 (Figures 2d and e). Conversely, p68 expres-
sion was reduced in HEK293Tcells transiently overexpress-
ing dominant negative TCF4 (DN-TCF4) (Figure 2f). We
have also observed p68 mRNA upregulation in TCF4 over-
expressing HEK293T cells (Figure S4 in Additional file 5).
Hence, it can be stated that the transcriptional upregu-
lation of p68 by ectopic expression of β-catenin or TCF4
indicates a direct involvement of the β-catenin/TCF4
transcription complex on p68 gene expression.
Wnt/β-catenin target c-Myc additionally contributes to
p68 gene expression
To decipher the significance of c-Myc in the Wnt
signaling-mediated tumourigenesis and its involvement in
p68 gene expression, if any, we have knocked down either
β-catenin or c-Myc in HEK293T cells followed by transi-
ently overexpressing Wnt3a. We have observed that the
resultant knockdown of either β-catenin or c-Myc reduces
the Wnt3a-dependent increase in the expression of p68 as
well as Wnt/β-catenin target c-Myc (Figure 3a). We have
also overexpressed either c-Myc or β-catenin in HEK293T
cells. We observed increased expression of p68 without
additional signaling by wnt3a overexpression (Figure S5 in
Additional file 6). We have further confirmed this regula-
tion by knocking down β-catenin in c-Myc-overexpressed
H1299 cells and analysed by IB and qRT-PCR (Figures 3b
and c). Consistently, upon knockdown of either TCF4,
c-Myc or p68 in mouse 4T1 cells using respective siRNAs,
we have found a substantial decrease in the expression
levels of p68 (Figures 3d and e). Surprisingly, here we have
also observed an unexpected result in p68 knockdown
cells where TCF4 was abruptly diminished indicating a
relation between them. All these results suggest that both
β-catenin/TCF4 and c-Myc are important factors in
regulating p68 gene expression.
Figure 1 (See legend on next page.)
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Figure 2 β-catenin/TCF4 is directly involved in p68 expression. (a) MCF7 cells were transfected with 1 and 2 μg of pEGFP-β-catenin.
Expressions of p68 and β-catenin target Cyclin D1 were analysed by immunoblotting (IB) with whole cell lysates (WCLs) prepared from 36 h
post-transfected cells. (b, c) MCF7 cells transfected with pEGFP-β-catenin. After 36 h, cells were kept in the presence of either translational (CHX)
or transcriptional (AD: actinomycin D) inhibitors for another 6 h and analysed by IB and qRT-PCR for expression of p68 and cycinD1 genes.
Densitometry values are given below the blots for IB. Exo and endo refers to the exogenous and endogenous band of β-catenin respectively.
(d, e) 4T1 and HEK293T cells were transfected with either β-catenin or tcf4. WCLs prepared from 36 h post-transfected cells and expressions
of target genes, as shown in the figure, were determined by IB using respective antibodies. Densitometry values are given below the blots.
(f) HEK293T cells were transfected with either WT-TCF4 or DN-TCF4, and expressions of p68 and β-catenin target cMyc were analysed by IB with
WCLs prepared from 36 h post-transfected cells.
(See figure on previous page.)
Figure 1 Canonical Wnt signaling upregulates p68 expression. (a) Whole cell lysates (WCLs) were prepared from MCF7, MDA-MB 231, 4T1,
H1299, HCT116 and HEK293T cells. β-catenin, transcription factor 4 (TCF4) and p68 protein levels were analysed by immunoblotting (IB). Densitometry
values are given below the blots. (b, c) Breast cancer patient samples (E-cadherin+ and E-cadherin-) were analysed by immunohistochemistry (IHC)
using antibodies against β-catenin, TCF4 and p68, as well as E-cadherin, to differentiate the samples. H scores of these samples were determined.
(d)Wnt3a-MCF7 and empty vector (EV)-MCF7 stable cells were immunostained with β-catenin (primary) and Alexa Fluor488 (secondary, Green)
antibodies and observed under fluorescence microscope to see its localisation pattern. Images were captured along with DAPI-stained nuclei at 600X
magnification (scale: 10 μm) (top). Cytoplasmic and nuclear extracts were prepared from Wnt3a-MCF7 and EV-MCF7 stable cells and were analysed for
β-catenin by IB. Densitometry values are given below the blots (bottom). (e) WCLs of Wnt3a-MCF7 and EV-MCF7 stable cells were analysed for Axin-2,
β-catenin, Cyclin D1 and p68 proteins by IB. Densitometry values are given below the blots. (f, g) MCF7, MDA-MB 231 and 4T1 cells were serum
starved for 24 h before treatment with Wnt3a condition medium (Wnt3a-CM). WCLs and total RNAs were prepared from 24 h post-treated cells to
check the expression of β-catenin, p68 and Cyclin D1 by IB and qRT-PCR.
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Figure 3 p68 gene expression is controlled by both β-catenin and c-Myc. (a) HEK293T cells were transfected with small interfering RNAs
(siRNAs) targeting either β-catenin or c-Myc. Scrambled siRNA-transfected cells were kept as control. After 24 h, cells were transfected with wnt3a
and kept for another 24 h. Whole cell lysates (WCLs) were prepared and proteins were analysed by immunoblotting (IB) as shown in the figure.
(b, c) β-catenin was knocked down in presence or absence of c-Myc overexpression by ectopic expression of myc-tagged c-Myc in H1299 cells.
WCLs and total RNAs of 36 h post-transfected cells were analysed for p68 expression by IB and qRT-PCR. (d, e) 4T1 cells were transfected with
siRNA targeting transcription factor 4 (TCF4), c-Myc, p68 or scrambled siRNA independently, and expression of respective proteins and mRNAs
were analysed by IB and qRT-PCR after 36 h of transfection.
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catenin signaling constitutes a positive feedback loop in
breast cancer cells
A positive feedback loop exists to regulate TCF4 expres-
sion mediated by β-catenin/p300 in the endometrial car-
cinoma (Em Ca) cells [51]. Since p68 is the co-activator
of β-catenin, we sought to analyse the importance of p68
in this type of feedback mechanism involving TCF4 ex-
pression. To examine this, we have selected MCF7 cells
where both TCF4 and p68 expressions are low compared
to other cancer cell lines.
We have searched the interconnecting effect of these
three crucial proteins in terms of their expression levels in
serum-starved Wnt3a-MCF7 stable cells. Our results
suggest that Wnt3a promotes expression of both p68 and
TCF4 proteins and mRNAs (Figures 4a and b), where c-
myc, cyclinD1 and axin2 were kept as positive controls.
This result indicates the existence of a possible feedback
loop. Furthermore, we also examined if overexpression of
either β-catenin or p68 in Wnt3a-MCF7 cells had any
additive effect on TCF4 expression and observed a signifi-
cant increase in the level of TCF4 (Figure 4c). To further
support the effect of p68-dependent regulation on TCF4,we have knocked down p68 and β-catenin individually in
Wnt3a-MCF7 cells and a significant inhibition of Wnt3a-
mediated increase of p68, TCF4 and c-Myc was observed
(Figures 4d and e). Again, to extend our understanding, we
have transiently overexpressed p68 in MCF7 cells to see
the effect on TCF4 expression by immunofluorescence.
Our results clearly show that p68-transfected cells express
more TCF4 (Figure 4f) compared to the untransfected
cells. Finally, to confirm this regulation, we have analysed
TCF4 promoter activity upon overexpression of either p68
or β-catenin. Here, the induction of TCF4 promoter activ-
ity is enhanced by approximately two-fold. This indicates
that both molecules are involved in TCF4 gene expression
(Figure 4g). Thus, p68 is indeed involved in the regulation
of TCF4 and maintains a positive feedback loop within the
canonical Wnt signaling pathway.
Recruitment of β-catenin/TCF4 on p68 promoter is
important for its enhanced expression
It has been well established that nuclear β-catenin is en-
gaged in TCF/LEF protein complexes on its target genes
[52]. To further elucidate the molecular mechanism(s)
for regulation of p68 gene expression we have cloned
Figure 4 p68 co-activates β-catenin-mediated TCF4 gene expression. To examine this Wnt3a expressing stable MCF7 cells (wnt3a) were
prepared and used where empty vector (EV)-MCF7 cells (ctrl) kept as control. (a, b) Stable MCF7 cells were serum starved for 48 h and analysed
for expression of various transcription factor 4 (TCF4) target genes by immunoblotting (IB) and qRT-PCR. (c, d) p68 and β-catenin were either
overexpressed (c) or knocked down using respective small interfering RNAs (siRNAs) (d) in Wnt3a-MCF7 cells and the expression pattern of p68,
TCF4 and c-Myc were examined. Densitometry values are given below the blots. (e) Expression of p68, TCF4 and c-Myc was determined in
EV-MCF7, Wnt3a-MCF7 and p68 knocked down Wnt3a-MCF7 cells by qRT-PCR. (f) Wnt3a-MCF7 cells were transfected with GFP-p68 (p68; green)
and immunostained with anti-TCF4 antibody (primary) and Alexa Fluor 594 (secondary; red) and visualised under fluorescence microscope. Images
were captured at 600X magnification (scale: 10 μm). (g) Tcf4 promoter activity was monitored in Wnt3a-MCF7 cells after overexpression of either
β-catenin or p68 by transient transfection using luciferase assay.
Guturi et al. Breast Cancer Research  (2014) 16:496 Page 8 of 15and analysed the human and mouse p68 promoter
sequences. The human p68 promoter contains three puta-
tive TCF4 binding elements corresponding to the core
consensus binding sequence (AC/GA/TTCAAAG) at
(324-CTTTGGA-317), (554-CGTCAAAG-547) and (706-
AACCAAAG-699) and one c-Myc site (380-CACGTGA-
374) upstream of the transcription start site. We have
mutated two of these three TCF4 sites and the c-Myc site
in both human and mouse p68 promoters, represented by
schematic diagrams (Figure 5a). The activity of the wild-
type p68 promoter was tested in various human cell lines,
with differential endogenous β-catenin levels, by luciferase
assay. Results indicate that the promoter activity is differ-
entially regulated (Figure 5b), correlating with β-catenin
levels (shown in Figure 1a). This regulation is also sup-
ported by increased promoter activity due to enhanced β-
catenin stabilization in LiCl-treated MCF7 cells (Figure 5c).But all the mutated p68 promoters pGL3-hp68-M1 (puta-
tive tcf4 site1), pGL3-hp68-M2 (putative tcf4 site2), pGL3-
hp68-M3 (c-myc site) and pGL3-hp68-M4 (all three sites)
showed reduced activity, even after β-catenin overex-
pression, when compared to the wild-type (Figure 5d).
The activity of these mutated promoters was found to re-
duce 2.9-, 5.9-, 3.0- and 16-fold respectively. The mouse
p68 promoter consists of one putative tcf4 site (1149-
GACAAAG-1143) and one c-Myc site (478-CACGTGA-
472; 100% conserved with human sequence) and the
activity of the mutated promoters was found to reduce
3.8- and 7.2-fold respectively for c-Myc alone, or when
both sites were mutated (Figure 5e).
Next, to examine whether TCF4/β-catenin complex can
bind directly to the endogenous p68 promoter, ChIP assay
was performed with antibody against β-catenin where
RNA polymerase II (Pol II) kept as a positive control. We
Figure 5 (See legend on next page.)
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Figure 5 β-catenin/TCF4 as well as c-Myc regulates p68 promoter. (a) Schematic representation of human and mouse p68 promoters.
(b) Activity of human p68 promoter (pGL3-hp68) was determined by luciferase assay in HEK293T, MCF7 and HCT116 cells after 36 h of
transfection. Values represent the firefly luciferase activities normalised to renilla luciferase activities. (c) Similarly, pGL3-hp68 activity was
determined in MCF7 cells treated with 20 mM lithium chloride (LiCl) for 2 h and 8 h. (d) Luciferase activities were determined in MCF7 cells
transfected with human wild-type pGL3-hp68, or mutated transcription factor 4 (TCF4) constructs like pGL3-hp68-M1, pGL3-hp68-M2, pGL3-hp68-M3
and pGL3-hp68-M4 independently, along with pEGFP-β-catenin. (e) Mouse p68 promoter (pGL3-mp68) activities were determined in MCF7 cells
transfected with either wild-type pGL3-mp68 or mutated TCF4 sites containing constructs pGL3-mp68-M1 and pGL3-mp68-M2 independently along
with pEGFP-β-catenin. (f) Cross-linked chromatin fragments of MCF7, MDA-MB 231 and HCT116 (human) as well as 4T1 (mouse) cells were
immunoprecipitated with respective antibodies as depicted in the figure. DNAs were isolated and PCR-amplified using primer sets designed from the
promoter regions of p68 and cyclin D1 genes. Densitometry values are given below the images. (g) MCF7 cells were treated with either Wnt3a-CM or
empty vector (EV)-CM (control). DNAs were isolated from cross-linked chromatins immunoprecipitated with the indicated antibodies and PCR-amplified
using primer sets designed from the promoter regions of p68 and RPL30 genes. Densitometry values are given below the images. (h) β-catenin
was knocked down in HCT116 and 4T1 cells using small interfering RNA (siRNA). Control siRNA (si ctrl)-transfected cells were kept as control. DNA
fragments were isolated from cross-linked chromatins immunoprecipitated with the indicated antibodies and PCR-amplified using primer sets designed
from the promoter regions of p68 and cyclin D1 genes. Input: 2.5% (f and g) or 5% (h) of total DNA isolated from cross-linked chromatin without
immunoprecipitation. Densitometry values are given below the images.
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moter as well as Cyclin D1 promoter (positive control)
by ChIP assay in four different cancer cell lines
and relatively more in the case of HCT116 and 4T1
(Figure 5f ). Similarly, in case of ChIP assay with anti-
body against TCF4, we found enrichment of p68 as well
as c-myc (Figure S6 in Additional file 7). Furthermore,
binding of β-catenin and c-Myc was enhanced in
Wnt3a-induced cells, keeping RPL30 promoter as the
negative control (Figure 5g). Next, β-catenin was knocked
down in these cells to investigate the binding of β-catenin
to the p68 promoter. It is evident from our results that the
occupancy of β-catenin on this promoter depends on the
level of β-catenin, thus supporting the involvement of the
β-catenin/TCF4 complex in p68 promoter activation
(Figure 5h and Figure S6 in Additional file 7). Therefore, it
indicates that the β-catenin/TCF4 complex indeed occu-
pies the p68 promoter and the binding is enhanced when
β-catenin gets activated. We have also found reduced c-
Myc binding in c-myc knockdown cells when compared
to the control (Figure S7 in Additional file 8). Altogether,
these results highlight that Wnt signaling enhances the β-
catenin/TCF4-mediated transcriptional activation of p68
promoter.
β-catenin/TCF4 mediated upregulation of p68 in breast
cancer cells leads to epithelial to mesenchymal transition
(EMT)
EMT is a process by which tumour-associated epithelial
cells obtain mesenchymal features resulting in reduced
cell-cell contact and increased motility; hence playing a
critical role in metastasis. Wnt signaling plays a vital role in
EMT [32,53]. Also, it has been reported that p68 mediates
EMT by facilitating nuclear translocation of β-catenin in
PDGF-induced cancer cells [32]. To decipher the involve-
ment of β-catenin/TCF4 in regulating p68 and induction of
EMT, we have overexpressed either β-catenin or TCF4 in
4T1 cells to enhance the p68 expression. As expected, wehave found upregulation of the EMT markers such as N-
cadherin, vimentin and VEGF (Figure 6a). Next, respective
siRNAs were used to selectively knockdown these genes in
MDA-MB 231 and 4T1 cells. Consequent downregulation
of EMT-associated markers in either tcf4 or p68 knock-
down cells, clearly indicates that increased p68 expression
is crucial for Wnt signaling-mediated EMT (Figure 6b).
To assess the anchorage-independent growth and
tumourigenic potential of Wnt3a-MCF7 cells, we con-
ducted colony-formation assays. The results indicate that
these cells form significantly more number of colonies in
comparison to EV-MCF7 cells. Also, individual knock-
down of β-catenin, TCF4, or p68 in Wnt3a-MCF7 cells
using respective siRNAs showed that knockdown of any of
these molecules resulted in reduced number of colonies,
indicating that the tumour-promoting ability of β-catenin
not only depends on TCF4 but also on p68 (Figure 6c). To
further ascertain the role of p68 in invasion of cancer cells,
a matrigel invasion assay was performed with Wnt3a-
MCF7 cells. These cells showed a significantly higher inva-
sive property compared to control cells (Figure 6d).
p68 enhances β-catenin/TCF4-dependent breast cancer
progression
To further confirm that p68 is crucial in Wnt signaling-
mediated tumourigenesis, the p68 knockdown and EV
stable cells were generated using the mouse syngeneic
4T1 cell line and p68 expression was checked (Figure 7a).
These cells were injected into the mouse mammary fat
pad to generate tumours. p68 knockdown resulted in re-
duced tumour volume, indicating the involvement of p68
in tumour progression (Figure 7b). The morphological fea-
tures of these tumours were ascertained by hematoxylin
and eosin (H&E) staining. IHC analysis of the tumour
regions confirmed the reduced expression of TCF4, β-
catenin and p68 as well as PCNA in the tumours gener-
ated with p68 knockdown cells when compared to the
tumours generated with EV control cells (Figure 7c). It
Figure 6 Wnt signaling-mediated p68 upregulation is important in the induction of EMT. (a) 4T1 cells were transfected with either
β-catenin or transcription factor 4 (TCF4). After 36 h, lysates were prepared and analysed for epithelial to mesenchymal transition (EMT) marker
proteins by immunoblotting (IB). (b) MDA-MB 231 and 4T1 cells were transfected with scrambled, tcf4 and p68 small interfering RNAs (siRNAs)
independently. After 48 h, whole cell lysates (WCLs) were prepared and analysed for EMT marker proteins by IB. (c) Wnt3a-MCF7 and empty
vector (EV)-MCF7 (control) stable cells were analysed for their anchorage-independent growth by formation of soft-agar colonies. Quantification
of the number of colonies and error bars are represented in the figure. Standard deviation (SD) was calculated from three independent biological
repeats. Statistical significance was analysed by Student’s t test (P <0.001) (top). Colony-forming ability of Wnt3a-MCF7 and EV-MCF7 cells were
determined after individual knockdown of β-catenin, tcf4 and p68 using respective siRNAs as depicted in the figure (bottom). (d) Wnt3a-MCF7
and EV-MCF7 (control) stable cells were analysed for their invasiveness using matrigel invasion assay. Error bars are represented in the figure.
SD was calculated from three independent biological repeats. Statistical significance was analysed by Student’s t test (P <0.001).
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the EMT markers, and increased expression of E-cadherin,
implying involvement of p68 in breast cancer progression
and metastasis.
All these results indicate that p68 upregulation
through β-catenin/TCF4 signaling is important for en-
hanced transactivation of β-catenin target genes and
thus attributes to the tumourigenic potential of breast
cancer cells.
Discussion
Wnt signaling has been found to be deregulated in most
cancers including breast and it plays an important role
in tumour progression by upregulating various factors.
β-catenin is majorly present in the cell membrane.
Wnt3a induces β-catenin stabilisation and promotes its
nuclear translocation [54,55]. Several reports state the
importance of p68 overexpression in cancer progression,
specifically in breast cancer, which is attributed to gene
locus amplification [56]. Here, we have tried to decipher
the regulation of p68 gene expression and demonstrated
that β-catenin is a critical mediator for p68 expression
in cancer cells. A previous study suggested a c-Mycconsensus site to be present in the p68 promoter, which
is involved in modulating p68 promoter activity [57-59].
The current study confirmed that the β-catenin/TCF4
complex regulates p68 promoter, and β-catenin target
c-Myc is also involved in this Wnt signaling-mediated
p68 gene expression. Our study, using mouse promoter
and 4T1 breast cancer cells, indicates that Wnt signaling-
mediated p68 gene regulation is conserved in mice. This
regulation also exists in human HEK293T and other can-
cer cells. Thus, β-catenin stabilization and nuclear accu-
mulation through Wnt signaling is vital for upregulation
of p68 gene expression. A recent study indicates the
presence of putative tcf4 sites in the rat p68 gene and
assigned as novel putative target [60]. Here, in this study,
we also found the existence of putative tcf4 binding sites
in both human and mouse p68 promoters. Our results
from promoter analysis and ChIP assay confirm that β-
catenin occupies the p68 promoter in both human and
mouse cell lines and the occupancy is further increased
when β-catenin is either overexpressed or induced by
Wnt signaling. Hence, we have emphasized that p68 up-
regulation by β-catenin/TCF4 may be one of the major
contributing factors in breast cancer progression.
Figure 7 p68 knockdown reduces breast tumour volume and expression of EMT markers in mice. (a) p68 expression level was
determined in p68 knockdown mouse 4T1 stable cells. Control short hairpin RNA (shRNA)-4T1 stable cells were kept as control. (b) Images of
mouse breast tumours after 16 days of injections in the mammary fat pad regions with stable cells expressing either control shRNA or p68
shRNA. Tumours obtained from the mammary fat pad regions were analysed for tumour volume (right panel). (c) Images of the hematoxylin and
eosin (H&E)-stained sections of the tumours and immunohistochemical analysis of the adjacent sections were performed with the indicated
antibodies as shown in the figure. Images were captured at magnifications of 200X.
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activator of β-catenin is also critically involved in the
Wnt signaling-mediated expression of TCF4 in breast
cancer cells. Thus, p68 appears to govern the critical
aspect of β-catenin nuclear function, which is the as-
sembly of a transcription activation complex, by regu-
lating TCF4 expression. Therefore, p68 gene regulationrepresents an important mechanism for controlling
canonical Wnt signaling-mediated proliferation and
tumourigenesis.
Nuclear import of β-catenin is another crucial phe-
nomenon in cells in response to Wnt signaling, and it
induces transition of epithelial cells to the mesenchymal
phenotype and tumour invasion [32,61]. Our study also
Figure 8 Schematic representation of β-catenin/TCF4-dependent p68 gene regulation for enhanced tumourigenesis in cancer. Based on
the previous reports and data from the current study, we propose this model. β-catenin can be stabilized and activated by aberrant Wnt signaling
that upregulates p68 gene expression, which in turn is involved in increasing transcription factor 4 (TCF4) gene expression and forms a positive
feedback loop that ultimately leads to enhanced expression of β-catenin target genes for enhanced tumourigenesis.
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stable cells showed more tumourigenic potential than the
EV-control cells. We have also shown that β-catenin/
TCF4-mediated p68 regulation plays an important function
in enhanced expression of EMT marker proteins in triple-
negative breast cancer cells MDA-MB 231, as well as in
mouse 4T1 cells. Again, our knockdown and overexpres-
sion studies support the involvement of p68 in the EMT
processes, as shown earlier [39]. We further infer that the
effect of p68 on the EMT progression is, in part, mediated
by its association with β-catenin/TCF4 complex. This is
consistent with the fact that many target genes of Wnt/β-
catenin signaling have EMT regulatory functions [62-64],
where p68 may play an important role by inducing β-
catenin mediated transcription.
Our study further suggests that β-catenin/TCF4 along
with c-Myc upregulate p68 in breast cancer cells favour-
ing EMT. Thus, β-catenin/TCF4 and p68 constitute a
positive feedback loop essential for β-catenin-mediated
processes involved in breast cancer progression. Here,
we propose a model (Figure 8) indicating regulation of
p68 gene expression in cancer cells by Wnt signaling
through a positive feedback mechanism involving β-
catenin and TCF4.Conclusions
Our findings not only provide an improved understand-
ing of the molecular mechanisms in the context of β-
catenin and tumourigenesis but also suggest that p68
may be a crucial target for therapeutic intervention in
breast cancer. Although, our data demonstrate that p68
gene regulation by Wnt/β-catenin signaling and its
implication in breast cancer, further work is required to
understand the p68 upregulation with reference to
cancer progression and metastasis.Additional files
Additional file 1: Table S1. List of primer sequences used in this study.
Additional file 2: Figure S1. Immunohistochemical analysis of p68,
β-catenin and TCF4 in normal human breast tissues samples. (a)
Immunohistochemistry was performed in normal human breast samples
(n = 10) to assess the status of E-cadherin, β-catenin, TCF4 and p68. (b)
The mean H scores of the desired proteins for each normal breast tissue
samples were represented by scatter plot. The images were captured at
100X magnification using BX61 microscope (Olympus).
Additional file 3: Figure S2. Wnt signaling promotes p68 expression.
HEK293T, HCT116 and H1299 cells were serum starved for 24 h before
treatment with either control condition medium (EV-CM), Wnt3a
conditioned medium (Wnt-CM) for another 24 h. Whole cell lysates (WCL)
Guturi et al. Breast Cancer Research  (2014) 16:496 Page 14 of 15were prepared and analysed by IB to examine the levels of β-catenin and
p68.
Additional file 4: Figure S3. GSK3β inactivation regulates p68
expression due to β-catenin stabilization. MCF7 cells were serum starved
for 24 h and treated with 20 mM Licl for the indicated periods. Whole cell
lysates (WCL) were prepared and analysed by IB to examine the levels of
β-catenin, p68 and Cyclin D1.
Additional file 5: Figure S4. TC4 regulates p68 transcript level. HEK293T
cells were transfected with either WT-TCF4 or control vector (ctrl). RNAs
were isolated from 36 h post-transfected cells and subsequently analysed by
qRT-PCR.
Additional file 6: Figure S5. β-Catenin along with c-Myc regulates p68.
HEK293T cells were transfected with β-catenin and c-Myc either alone or
in combination. WCLs were prepared after 36 h of transfection and
analysed by IB to examine the levels of β-catenin, p68 and c-Myc.
Additional file 7: Figure S6. β-catenin/TCF4 complex occupies the p68
promoter. (a) Cross-linked chromatins of MCF-7, MDA-MB 231, 4T1,
HCT116 cells were immunoprecipitated with anti-TCF4 antibody. (b)
Cross-linked chromatins of 4T1 and HCT116 cells were transfected with
either scrambled siRNA or β-catenin siRNA, and immunoprecipitated with
anti-β-catenin antibody. The relative values in both (a) and (b) were
normalised to negative control IgG. SEMs were calculated from two
independent experiments.
Additional file 8: Figure S7. c-Myc occupies the p68 promoter.
Cross-linked chromatin of HCT116 cells transfected with either scrambled
or c-Myc siRNA were immunoprecipitated with anti-c-Myc antibody as
indicated and subsequently qRT-PCR was performed. The relative values
were normalised to IgG (negative control). SEM was calculated from two
independent experiments.
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